Discontinuation of Flovent in Dec 2023: Guidance from DOH
Regarding the discontinuation of Flovent HFA and Diskus expected at the end of 2023, NYSDOH is proactively reviewing the status of medications within NYRx to ensure patients have a seamless transition to available products. The Corticosteroids-Inhaled drug class was reviewed at the September 2023 Drug Utilization Review Board (DURB) Meeting and the DURB recommended to move Alvesco and Arnuity Ellipta to preferred. As a result, NYRx has removed the PA requirement from these two agents and will update the Preferred Drug List (PDL) with the general DURB meeting updates in November. To view other drugs that were reviewed in September, please refer to the DURB September 2023 Meeting Summary. NYSDOH will continue to monitor the supply of brand Flovent HFA in the marketplace and reassess the need to adjust the status of the generic. Flovent Diskus does not have a generic available, as market supply runs out patients will need to be switched to another product.
Note: Prescribers should review and prescribe preferred products whenever possible. The drugs that are preferred generally do not require prior authorization when prescribed according to FDA labeling, unless otherwise indicated. For a resource containing only preferred drugs, please refer to the NYRx Preferred Drug Quick List.
The NYRx Education & Outreach (E&O) team supports NYSDOH with training and education regarding NYRx, the Medicaid Pharmacy Program. The NYRx E&O team serves as a liaison between NYRx and the Medicaid Managed Care Organizations (MCOs) and assists with complex pharmacy cases. In addition, this team offers specialized support to NYRx stakeholders that care for member populations who may have HIV/AIDs, Hemophilia, Substance Use Disorder, Hepatitis C, Serious Mental Illness, or are in Foster Care. To learn more about NYRx E&O, please visit: NYRx E&O Homepage, send an email to [email protected] or call the NYRx E&O Call Center at (833) 967-7310 Monday-Friday 8am-5pm ET.
Share
Registration Now Open Medical Matters CME Webinar Public Health! What is it Good for? Wednesday June 12, 2024 @ 7:30am Join a group of public health experts on June 12th at 7:30am for the next Medical Matters webinar, Public Health! What is it Good for? This webinar will be a panel discussion examining the evolving […]
-
Revised Wrongful Death Liability Expansion Legislation Does Not Alter Fundamental Concerns About Harm to Healthcare System New York’s continued designation as one of the worst states in the country in which to be a physician Best & Worst States for Doctors in 2024 (wallethub.com) is a major contributing factor to patient access to care shortages […]
-
MSSNY Joins with Patient Advocates to Reduce Prior Authorizations Burdens MSSNY organized meetings with several key legislators this past week to urge passage of prior authorization reform measures this year, including A.7268 (Weprin)/S.3400 (Breslin) and A859-A(McDonald)/S.2680-A (Breslin). Joining MSSNY in these meetings were representatives from the NY State Psychiatric Association, the American College of Obstetricians […]
-
Final Weeks of Session Brings Numerous Concerning Scope Expansion Bills The recently enacted State Budget importantly rejected numerous proposals that would have threatened patient safety by removing the important oversight and/or collaboration that physicians provide in the delivery of patient care. However, as we enter the final three weeks of the scheduled 2024 Legislative Session, […]
